BHC
Bausch Health Cos Inc
NYSE · Pharmaceuticals
$5.88
+0.15 (+2.62%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 12.92B | 12.36B | 465.96M | 415.01M | 424.70M |
| Net Income | -61,752,823 | -53,184,249 | 102.50M | 120.28M | 97.22M |
| EPS | — | — | — | — | — |
| Profit Margin | -0.5% | -0.5% | 22.0% | 29.0% | 22.9% |
| Rev Growth | +4.5% | +4.5% | +23.7% | +10.0% | +0.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 1.42B | 1.42B | 650.08M | 706.86M | 615.00M |
| Total Equity | 31.77M | 31.77M | 1.73B | 1.48B | 1.79B |
| D/E Ratio | 44.72 | 44.72 | 0.38 | 0.48 | 0.34 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 3.55B | 3.23B | 190.54M | 156.90M | 174.68M |
| Free Cash Flow | — | — | 97.27M | 115.51M | 151.31M |